Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Herantis Pharma Plc – Company Release – December 11 2025, at 14.15 EET.
Herantis Pharma Plc Financial Reporting and Annual General Meeting in 2026
In 2026 Herantis Pharma Plc will publish its financial reports as follows
| Report | Release date |
| Financial Statements Release 2025 | 5.3.2026 |
| Annual Report for 2025 | 30.3.2026 |
| H1/2026 Half-a year report January-June | 20.8.2026 |
Annual General Meeting 2026
Herantis Pharma’s Annual General Meeting is scheduled for 23 April 2026. The Board of Directors will convene the meeting at a later date. The deadline for submission of proposals for the Annual General Meeting is 5 March 2026.
The company's financial reviews are published in both Finnish and English through company releases and can be accessed on the company's website at https://herantis.com/investors/releases/.
Herantis Pharma Plc observes a 30-day silent period prior to the publication of its financial statements and interim reports, during which the company does not comment on its financial position or outlook, nor meets with representatives of the capital markets or financial media.
Herantis Pharma’s financial reporting calendar, silent periods, and the deadline for submitting proposals to the Annual General Meeting can also be found on our website at https://herantis.com/investors/calendar/.
Further information
Tone Kvåle, CFO
Tel: +47 915 19576
E-mail: ir@herantis.com
Certified Advisor
UB Corporate Finance Oy
Tel: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease. The Company's lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson's disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson's patients.
Herantis is listed on the Nasdaq First North Growth Market Finland. www.herantis.com